Document:

EX-10.11

 Exhibit 10.11 

AMENDMENT NO. 1 
 TO

 LICENSE AND COMMERCIALIZATION AGREEMENT 

This Amendment No. 1, dated as of August 27, 2018 (this “Amendment”), to the License and Commercialization Agreement (the
“Agreement”), dated as of July 28, 2017, is entered into between Bioprojet Societe Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at
30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet SCR”) and together with its Affiliates, including Bioprojet Pharma SARL and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability
company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this
Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be referred to herein, together, as the “Parties” and, individually, as a “Party.” 

WHEREAS, the Parties have previously entered into the Agreement; and 

WHEREAS, in accordance with the Agreement, the Parties desire to amend the Agreement, upon the terms and subject to the conditions set forth
herein. 
 NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the adequacy and receipt of
which hereby are acknowledged, the Parties hereby agree as follows: 
 1.    Subject to timely payment of the milestone
amount pursuant to Section 6.2(i), Section 6.2(iv) of the Agreement is hereby amended by deleting the clause “, and pay any corresponding milestone payment within fifteen (15) days of such achievement.” and replacing it with
the following clause: 
 “, and pay any corresponding milestone payment (a) payable under Section 6.2(i) or
Section 6.2(iii) within fifteen (15) days of such achievement and (b) payable under Section 6.2(ii), together with a one-time, non-creditable, non-refundable payment in the amount of Two Million ($2,000,000) USD, within ninety (90) days of such achievement.” 

2.    This Amendment shall be governed, and construed and enforced in accordance with, the laws of England and Wales,
without reference to conflict of law principles. 
 3.    This Amendment may be signed in counterparts, each of which
shall be an original, with the same effect as if the signatures hereto were upon the same instrument. This Amendment shall become effective when each Party shall have received a counterpart hereof signed by the other Party. Until and unless each
Party has received a counterpart hereof signed by the other Party hereto, this Amendment shall have no effect, and no Party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other
communication). 

 4.    Except as otherwise provided herein, the Agreement shall remain
unchanged and in full force and effect. 
 5.    From and after the execution of this Amendment by the Parties, any
reference to the Agreement shall be deemed to be a reference to the Agreement as amended by this Amendment. 
 [SIGNATURE PAGE FOLLOWS]

 IN WITNESS WHEREOF, the Parties have executed this Amendment as of the day and year first
written above. 
  

			
	BIOPROJET SOCIÉTÉ CIVILE DE RECHERCHE
		
	By:	 	 /s/ Jeanne-Marie Lecomte

	Name:	 	Jeanne-Marie Lecomte
	Title:	 	Chairman
	
	HARMONY BIOSCIENCES, LLC
		
	By:	 	 /s/ John Jacobs

	Name:	 	John Jacobs
	Title:	 	EVP & Chief Commercial Officer

 [Signature Page to Amendment No. 1 to License and Commercialization Agreement]EX-10.12

 Exhibit 10.12 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

TRADEMARK LICENSE AGREEMENT 

This Trademark License Agreement (this “Agreement”) is entered into this
23rd day of August, 2018 (the “Effective Date”) by and among Bioprojet Europe, Ltd., a company organized under the laws of Ireland and having its place of business at 101 Furry
Park Road, Killester, Dublin 5, D05KD52 Ireland (“Licensor”), Bioprojet Société Civile de Recherche, an independent (privately owned) research company organized under the laws of France and having its principal place
of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its
principal place of business at 1033 Skokie Boulevard, Suite 600, Northbrook, Illinois 60062 (“Licensee”). Licensor, Bioprojet, and Licensee hereafter are collectively referred to as the “Parties,” and each
individually is referred to as a “Party,” where no other distinction is required. 
 BACKGROUND 

WHEREAS, in connection with its business, Licensor is the owner of U.S. Trademark Registration No. 4,680,400 for the mark WAKIX
designating “pharmaceutical products for the treatment of narcolepsy or other sleep disorders” in International Class 5, U.S. Trademark Application No. 87377316 for the mark WAKIREM designating “pharmaceutical
preparations for the treatment of narcolepsy or other sleep disorders” in International Class 5 and the trade name “Bioprojet”. 

WHEREAS, Licensor is an affiliate of Bioprojet, owner of certain registered trademarks and trademark applications in the United States of
America designating products developed by Bioprojet. 
 WHEREAS, Licensee and Bioprojet are parties to a License and Commercialization
Agreement dated July 28, 2017 (the “L&C Agreement”), pursuant to which, among other things, Bioprojet granted to Licensee, and Licensee obtained certain exclusive rights and licenses under the Licensed Assets to
Commercialize the Product in the Field and the Territory, all as defined and more specifically set forth therein. All capitalized terms not otherwise defined herein shall have the meaning assigned to them in the L&C Agreement. 

WHEREAS, pursuant to the terms of the L&C Agreement, Bioprojet granted to Licensee the exclusive right and license to use the trademarks
identified on Exhibit A, attached hereto and made a part hereof, Bioprojet’s trade name and any other product-specific trademarks that Bioprojet and Licensee mutually agree upon
for use with the Product in the Territory during the Term (each, individually, the “Trademark”, and, collectively, the “Trademarks”) in the United States and its territories, commonwealths and protectorates
(including Puerto Rico) (the “Territory”) for the marketing, sale and promotion of the Product. 

 WHEREAS, the Parties have agreed upon the brand guidelines for the Product as set forth on
Exhibit B, attached hereto and made a part hereof. 
 WHEREAS, the Parties are desirous of entering into this
Agreement to more fully set forth the terms on which the rights to use the Trademarks and the Bioprojet trade name, as provided in the L&C Agreement, are granted to Licensee. 

NOW THEREFORE, in consideration of the mutual promises and covenants contained herein and in the L&C Agreement and for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows: 
 1.    Grant
of License; Consideration. 
 (a)    Licensor hereby grants to Licensee an exclusive license to use (and grant
sublicenses to Licensee’s Affiliates and Third Parties to use in accordance with the provisions of the L&C Agreement) the Trademarks and the Bioprojet trade name in the Territory for the sole purpose of marketing, selling, distributing and
promoting the Product in accordance with this Agreement and, as applicable, the L&C Agreement. Licensor further agrees to be bound by the terms and conditions of the L&C Agreement to the extent necessary for Licensee to fully receive the
rights granted by Bioprojet thereunder with respect to the Trademarks and other matters addressed in this Agreement. 

(b)    In consideration for the Trademark License, following the First Commercial Sale of Product and for twenty
(20) years thereafter (the “Initial Term”), Partner shall pay to Bioprojet the Trademark Royalty Payments (as defined in the L&C Agreement) pursuant to Section 6.3(b) of the L&C Agreement. 

2.    Term. 

(a)    This Agreement shall commence on the Effective Date and shall continue for the Initial Term, unless sooner
terminated as provided herein. 
 (b)    This Agreement may be extended, at Licensee’s option on a non-exclusive basis, for two (2) further renewal periods of five (5) years each, commencing upon the expiration of the Initial Term (each, a “Renewal Term”), provided that:
(i) Licensee is not in breach of any material obligation under this Agreement as of the date of Licensee’s exercise of such renewal or extension hereof and as of the commencement of each Renewal Term; and (ii) Licensee gives written
notice to Licensor by no later than six (6) months prior to the expiration of the then current term of its exercise of Licensee’s option for the following Renewal Term. All terms and conditions of this Agreement shall remain in full force
and effect for the Renewal Term(s), unless the Parties mutually agree otherwise in writing signed by or on behalf of all Parties. The Initial Term and the Renewal Term(s), if any, shall constitute the “Term.” The Term shall also be
deemed to refer to only the Initial Term if Licensee’s first renewal option is not exercised. 

3.    Display. 

(a)    Except as set forth in this Section 3, all packaging materials, labels and Marketing Materials for the Product
shall display one of the Trademarks, and no other 

  
 2 

 
product-specific trademarks or branding. Where possible, Licensee shall utilize the mark “WAKIX” as the source identifier for the Product, or any
other registered trademark designated as such by Licensor. If “WAKIX” cannot be used for legal, regulatory or other material reasons outside the Parties’ reasonable control, in the Territory, Licensee shall utilize the alternative
registered trademark, chosen by Licensor as the Trademark. If neither “WAKIX” or the alternative trademark can be used for legal, regulatory or other material reasons outside the Parties’ reasonable control, in the Territory, the
Parties will agree as to another Trademark to be filed and maintained by Licensor for use in the Territory and such other trademark shall be deemed to be included in the definition of “Trademarks” herein. 

(b)    The Product shall be sold in the Territory under the trade name of Licensee; provided, however that to the extent
permissible under applicable law within the Territory, such packaging materials, labels and Marketing Materials shall also display the trade name of Licensor in reasonable size and prominence, as reasonably approved by Licensor. The trademarks of
Licensee, trade dress, style of packaging and the like with respect to the Product in the Territory may be determined by Licensee in a manner that is consistent with Licensee’s standard trade dress and style, but shall be subject to the
approval by the JSC (as defined in the L&C Agreement). 
 4.    Approval of Packaging and Promotional
Materials. Licensee shall submit representative Marketing Materials, packaging and Product displaying the Trademarks and/or Licensor’s trade name to Licensor for Licensor’s review and approval prior to the first use of such Marketing
Materials, packaging or Product and prior to any subsequent change or addition to such Marketing Materials, packaging or Product; provided that if Licensor has not responded within thirty (30) calendar days after the submission of such
Marketing Materials, packaging or Product, Licensor’s approval will be deemed to have been received. 

5.    Enforcement. 

(a)    If either Party becomes aware of any actual or threatened infringement of any Trademark in the Territory, such Party
shall promptly notify the other Party in writing. 
 (b)    Licensee shall have the first right, at its own expense, to
initiate infringement proceedings or take other appropriate actions against an infringement of any Trademark in the Territory and/or to defend any actions or proceedings involving the Trademarks in the Territory, as the case may be. 

(c)    If Licensee does not initiate proceedings or take other appropriate action within ninety (90) calendar days
after receipt of a request by Licensor to do so, then Licensor shall be entitled, at its own expense, to initiate infringement proceedings or take other appropriate action against an infringement of a Trademark in the Territory, or to defend any
actions or proceedings involving or affecting a Trademark in the Territory, as the case may be. 
 (d)    The Party
conducting such action shall have full control over the conduct of such action, including settlement thereof; provided, however, that the Party conducting such action may not settle any such action, or make any admissions or assert any position in
such action, in a manner that would materially adversely affect the Trademarks in the Territory nor the rights or interests of the other Party, without the prior written consent of the other Party, which shall not be unreasonably withheld,
conditioned or delayed. 

  
 3 

 (e)    In any event, the Parties shall keep one another informed of the
status of their respective activities regarding any litigation in the Territory involving a Trademark or settlement thereof and shall assist one another and cooperate in any such litigation at the other’s reasonable request (including joining
as a party plaintiff to the extent necessary and requested by the other Party) and the other’s expense. 

(f)    Licensee and Licensor shall recover their respective actual out-of-pocket expenses, or proportionate percentages thereof, associated with any litigation against infringers undertaken pursuant to this Section 5 or settlement thereof from any resulting recovery
made by either Party. Any excess amount of such a recovery shall be allocated between Licensee and Licensor as set forth in the following table to the extent such recovery represents damages pertaining to the infringement of a Trademark in the
Territory: 
  

									
	 Aggregate Recovery Amount in Excess of
Out-of-Pocket

Expenses               
                                         
                        
	  	Percentage
Payable to
Licensor	 	 	Percentage
Payable to
Licensee	 
	 Portion of such recovery less than or equal to US$200,000,000
	  	 	13	% 	 	 	87	% 
	 Portion of such recovery greater than US$200,000,000 and less than or equal to
US$400,000,000
	  	 	15	% 	 	 	85	% 
	 Portion of such recovery greater than US$400,000,000 and less than US$600,000,000
	  	 	21	% 	 	 	79	% 
	 Portion of such recovery greater than US$600,000,000
	  	 	24	% 	 	 	76	% 

 6.    Representations and undertakings. 

6.1.    Representations of Licensor. Licensor represents and warrants that: (a) it owns outright all marketable
and other title to the Trademarks, free and clear of all liens, security interests, encumbrances, and/or any other transfer of rights; (b) it is not currently a party to any agreement which grants any other party the right to use the Trademarks
in the Territory; (c) to Licensor’s knowledge, the use of the Trademarks does not infringe upon any trademark owned by any Third Party (as defined in the L&C Agreement) in the Territory; and (d) Licensor has full power and
authority to enter into this Agreement, to perform its obligations hereunder and to grant the rights it grants herein. 

6.2.    Representations and undertakings of Licensee. 

(a)    Licensee represents and warrants that, as of the Effective Date, it has not filed or registered, directly or
indirectly, through any of its Affiliates or Third Party, in any country whatsoever, any designation, including as a trademark, in any International Classes, a company name, trade name, shop sign, domain name, incorporating the designations
“WAKIX”, “WAKIREM” or “BIOPROJET”, that would be identical to the Trademarks or the Bioprojet trade name or likely to create a risk of confusion with the same in the mind of the consumers. 

  
 4 

 (b)    Licensee acknowledges that (i) nothing in this Agreement
shall be construed as granting Licensee any right whatsoever (including any right of ownership) in any of the Trademarks or the Bioprojet trade name, in existence now or thereafter within and outside the Territory, and (ii) the Licensor is sole
owner of all proprietary rights and interest in and to the Trademarks and the Bioprojet trade name. 
 (c)    Licensee
undertakes never to challenge, oppose or seek cancellation of the Trademarks and/or the Bioprojet trade name, or any other trademark or trade name of the Licensor and/or Bioprojet or application filed by the Licensor and/or Bioprojet incorporating
the designations “WAKIX”, “WAKIREM” and/or “BIOPROJET”. 
 (d)    Licensee undertakes,
during the Term of this Agreement never to file or register directly or indirectly, through any of its Affiliates or Third Party, in any country whatsoever, any designation, including as a trademark, in any International Classes, a company name,
trade name, shop sign, domain name, incorporating the terms “WAKIX”, “WAKIREM” and/or “BIOPROJET”, that would be identical to the Trademarks or the Bioprojet trade name or likely to create a risk of confusion with the
same in the mind of the consumers. 
 7.    Termination and Effect Thereof. 

(a)    This Agreement shall terminate automatically upon termination of the L&C Agreement. 

(b)    On the termination or expiration of this Agreement, all the rights of Licensee hereunder to use the Trademarks and
the Bioprojet trade name shall terminate and automatically revert to Licensor and Licensee shall cease to use the same except as expressly permitted pursuant to Section 14.2 of the L&C Agreement. Licensee shall take all such steps as
Licensor may reasonably request to give effect to the termination of the license to the Trademarks and the Bioprojet trade name in the Territory and to record any documents that may be required to evidence the termination of such license and
transfer to Licensor of all rights, registrations, recordations and the like for such Trademarks and/or trade name. 

8.    Property of Licensor; Maintenance of Trademarks; Recordation of Licenses. To the extent any rights in and to
the Trademarks and the Bioprojet trade name belonging to Licensor are deemed to accrue to Licensee, as a matter of law or otherwise, Licensee hereby assigns any and all such rights, at such time as they may be deemed to accrue, including all related
goodwill, to Licensor. Licensor (or its designee) shall be responsible for filing, registering, renewing and maintaining at Licensor’s sole cost and expense and in its own name (to the extent permitted by applicable law), appropriate
registrations for the Trademarks and/or Bioprojet trade name in the Territory. Any necessary recordation of the Agreement with governmental agencies in the Territory shall be performed by Licensee at its sole cost and expense. If the Licensor
intends to allow any of the Trademarks to lapse, the Licensor shall notify the Licensee and provide them with at least thirty (30) days’ notice and offer to assign such Trademarks to the Licensee for consideration to be agreed on an
arm’s length basis between the Parties. 
 9.    Indemnification. Subject to the other indemnification
mechanisms set forth in the L&C Agreement, which shall prevail in case of conflict with this Section, Licensor hereby 

  
 5 

 
indemnifies Licensee and its subsidiaries and affiliates, and the officers, directors, shareholders, principals, employees, agents and representatives of each of the foregoing, and their
respective successors and permitted assigns individually and in the aggregate, against and hold each and all of them harmless from any and all claims, losses, liability, damages, costs and expenses (including reasonable attorneys’ and
accountants’ fees and expenses) to the extent arising from Licensee’s use of the Trademarks. The provisions of this Section and the obligations of Licensee set forth herein shall survive termination of this Agreement. 

10.    Applicable Law, Jurisdiction. This Agreement and all questions regarding its validity or interpretation, or
the breach or performance of this Agreement and resolution of all disputes and any remedies relating thereto, shall be governed by and construed and enforced in accordance with the laws of England and Wales, without reference to its conflict of law
principles. Any dispute, controversy, difference or issue which may arise between the Parties, unless settled by mutual consultation in good faith, shall be submitted to arbitration for final resolution in the conditions set forth in the L&C
Agreement. The Parties agree and acknowledge that all prior discussions concerning the subject matter of this Agreement are merged into and superseded hereby, and there are no oral or other undertakings. 

11.    Severability. In the event that any term or provision of this Agreement shall, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the
same shall have been held to be invalid, illegal or unenforceable, had never been contained herein. 
 12.    Entire
Agreement. This Agreement, together with the L&C Agreement, represents the entire understanding between the Parties hereto with respect to the subject matter hereof and supersedes all previous representations, understandings or agreements,
oral or written, between the Parties with respect to the subject matter hereof. This Agreement cannot be modified except by a written instrument signed by the Parties hereto. Any discrepancy between this Agreement and the L&C Agreement shall he
governed by the L&C Agreement. 
 13.    Further Assurances. The Parties shall prepare and execute such
further documentation and perform such further actions, including the recordation of such documentation with appropriate authorities, as may be reasonably requested by either of the Parties hereto, to evidence or give effect to this Agreement or to
enforce the Trademarks. 
 14.    Binding Agreement. This Agreement will be binding upon, and inure to the
benefit of, the Parties and their respective successors, permitted sub-licensees, assigns and transferees, and agents. 

15.    Assignability. This Agreement shall not be assignable by either Party to any Third Party hereto without the
written consent of the other Party hereto. Either Party shall have the right to assign this Agreement to an Affiliate (as defined in the L&C Agreement), with the prior written consent of the other Party hereto (which shall not be unreasonably
withheld, conditioned or delayed); provided that the assigning Party guarantees the performance of this Agreement by such Affiliate and such Affiliate agrees in a writing delivered to the non-assigning Party
to assume all of the rights and obligations of the assigning Party under this Agreement; and further provided that 

  
 6 

 
if the non-assigning Party reasonably believes such assignment could result in material adverse tax consequences to the
non-assigning Party, the non-assigning Party shall have no obligation to consent to the proposed assignment. Subject to the foregoing, this Agreement shall inure to the
benefit of each Party hereto, its successors and permitted assigns. Any assignment of this Agreement in contravention of this Section 16 shall be null and void. 

16.    Confidentiality. Section 10 of the L&C Agreement shall apply mutatis mutandis to this
Agreement. 
 17.    Section Headings. Section headings are included solely for convenience, are not
considered to be a part of this Agreement and are not intended to be full and accurate descriptions of the contents of such provisions. 

18.    Notices. All notices, requests, consents, demands, approvals and other communications, including the service
of process, hereunder shall be deemed to have been duly given, made or served if in writing and delivered personally or sent by overnight carrier that requires the addressee to acknowledge receipt thereof to the respective Parties to this Agreement
as set forth in the L&C Agreement. Informal communications between the Parties may be properly transmitted by e-mail. 

19.    Variation. No variation of this Agreement shall be valid or effective unless it is in writing, refers to
this Agreement and is duly signed or executed by, or on behalf of, each Party. 
 20.    No Partnership or
Agency. Nothing in this Agreement constitutes, or shall be deemed to constitute, a partnership between the Parties nor make any Party the agent of another Party. 

21.    Survival. Provisions which by their terms or intent are to survive termination of this Agreement shall do
so. 
 22.    Waiver. No failure, delay or omission by either Party in exercising any right, power or remedy
provided by law or under this Agreement shall operate as a waiver of that right, power or remedy, nor shall it preclude or restrict any future exercise of that or any other right or remedy. No single or partial exercise of any right, power or remedy
provided by law or under this Agreement shall prevent any future exercise of it or the exercise of any other right, power or remedy. 

23.    Third Party Rights. No one other than a Party to this Agreement, their successors and permitted assignees,
shall have any right to enforce any of its provisions. 
 24.    Counterparts. This Agreement may be executed in
multiple counterparts, each of which shall be regarded for all purposes as an original, and such counterparts shall constitute a single document. The Parties may also exchange signatures (in counterparts) by facsimile or e-mail transmission, which signatures shall be deemed to be original, valid and binding. 
 [Signature Page
Follows] 

  
 7 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

			
	BIOPROJET EUROPE, LTD.
		
	By:	 	 /s/ Jean-Guillaume Lecomte

	Name:	 	Jean-Guillaume Lecomte
	Title:	 	Director
	
	BIOPROJET SOCIETE CIVILE DE RECHERCHE
		
	By:	 	 /s/ Jean-Marie Lecomte

	Name:	 	Jean-Marie Lecomte
	Title:	 	CEO
	
	HARMONY BIOSCIENCES, LLC
		
	By:	 	 /s/ John Jacobs

	Name:	 	John C. Jacobs
	Title:	 	Chief Executive Officer

  
 8 

 Exhibit A 

Trademarks 

COUNTRIES / TRADEMARKS 

26 juin 2017 
 Country
    United States of America 
  

													
	 Trademark
	  	 Registered Owner
	  	Classes	  	 No / Date

Application
	  	 No / Date

Registration
	  	Status	  	Next Renewal
Date
	 WAKREM
	  	BIOPROJET EUROPE LTD	  	5	  	 87377316

20 mars 2017
	  		  	Pending	  	
	 WAKIX
	  	BIOPROJET EUROPE LTD	  	5	  	 1211316

25 juin 2014
	  	 4600400

03 Novr. 2015
	  	Registered	  	25-juin-2024

  
 9 

 Exhibit B 

Brand Guidelines 

[***] 

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]